Challenges in pharmacogenetics

被引：8
作者：
Cascorbi, Ingolf [1 ]
Bruhn, Oliver [1 ]
Werk, Anneke N. [1 ]
机构：
[1] Univ Hosp Schleswig Holstein, Inst Expt & Clin Pharmacol, D-24105 Kiel, Germany
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 69卷
关键词：
CYP2C19; GENOTYPE; CYP2D6; POLYMORPHISM; ASSOCIATION; CLOPIDOGREL; METABOLISM; IMPACT; RISK; PHARMACOKINETICS; HYDROXYLATION;
D O I：
10.1007/s00228-013-1492-x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The attempt to optimize drug treatment of patients by using evidenced-based medicine considering individual physiological and disease-related conditions is standard of modern medicine. Pharmacogenetics (PGx) has contributed to individualization considering hereditary genetic information; however, increasingly, pharmacogenomics is becoming essential, particularly in relation to modern oncology. New technologies such as next-generation sequencing and rapid development of computational and information sciences will help to better elucidate the consequences of genetic variation, considering also epigenetics and gene-environmental interactions and their translation into clinically relevant individual phenotypes. This review highlights the current challenging and most promising examples of PGx.
引用
收藏
页码：S17 / S23
页数：7
相关论文
共 49 条
  • [1] Untitled
    Abrahams, Edward
    [J]. PERSONALIZED MEDICINE, 2009, 6 (05) : 479 - 480
  • [2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [3] CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline
    Alfaro, CL
    Lam, YWF
    Simpson, J
    Ereshefsky, L
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) : 155 - 163
  • [4] A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
    Anderson, Jeffrey L.
    Horne, Benjamin D.
    Stevens, Scott M.
    Woller, Scott C.
    Samuelson, Kent M.
    Mansfield, Justin W.
    Robinson, Michelle
    Barton, Stephanie
    Brunisholz, Kim
    Mower, Chrissa P.
    Huntinghouse, John A.
    Rollo, Jeffrey S.
    Siler, Dustin
    Bair, Tami L.
    Knight, Stacey
    Muhlestein, Joseph B.
    Carlquist, John F.
    [J]. CIRCULATION, 2012, 125 (16) : 1997 - +
  • [5] NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation
    Barraclough, Katherine A.
    Isbel, Nicole M.
    Lee, Katie J.
    Bergmann, Troels K.
    Johnson, David W.
    McWhinney, Brett C.
    Ungerer, Jacobus P. J.
    Cambell, Scott B.
    Leary, Diana R.
    Bialasiewicz, Seweryn
    Rockett, Rebecca J.
    Staatz, Christine E.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 1025 - 1032
  • [6] Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs
    Bertilsson, L
    Dahl, ML
    Dalén, P
    Al-Shurbaji, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) : 111 - 122
  • [7] Transient Receptor Potential Channel Polymorphisms Are Associated with the Somatosensory Function in Neuropathic Pain Patients
    Binder, Andreas
    May, Denisa
    Baron, Ralf
    Maier, Christoph
    Toelle, Thomas R.
    Treede, Rolf-Detlef
    Berthele, Achim
    Faltraco, Frank
    Flor, Herta
    Gierthmuehlen, Janne
    Haenisch, Sierk
    Huge, Volker
    Magerl, Walter
    Maihoefner, Christian
    Richter, Helmut
    Rolke, Roman
    Scherens, Andrea
    Ueceyler, Nurcan
    Ufer, Mike
    Wasner, Gunnar
    Zhu, Jihong
    Cascorbi, Ingolf
    [J]. PLOS ONE, 2011, 6 (03):
  • [8] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 176 - 180
  • [9] The impact of the CYP2D6 polymorphism on haloperidol pharmacoldnetics and on the outcome of haloperidol treatment
    Brockmöller, J
    Kirchheiner, J
    Schmider, J
    Walter, S
    Sachse, C
    Müller-Oerlinghausen, B
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) : 438 - 452
  • [10] IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE
    BROSEN, K
    OTTON, SV
    GRAM, LF
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) : 543 - 549
12345